Envirotainer sees improvements in access to biopharmaceuticals across the globe

Better access to treatments supported by booming secure cold chain shipments

Stockholm, March 22, 2022: Envirotainer, the specialist in secure cold chain solutions for the shipment of pharmaceuticals, has reported a 24 per cent increase in the volume of life-saving medicines shipped around the world in its temperature-controlled units. In 2021 the Envirotainer fleet moved ~600 million doses. In 2022 this grew to ~744 million doses (272 000 pallets).

The news comes just months after Envirotainer extensively expanded its production site in Rosersberg, just north of Stockholm in November 2022.

Already the largest site in the world in terms of output, the investment will allow Envirotainer to grow its current fleet of 7,500 FAA and EASA certified containers by another 1,300 in 2023.

The Envirotainer fleet covers more than 2,000 pharmaceutical trade lanes in over 100 countries and 300 airports. To enable the shipment of ever-increasing volumes of vaccines and treatments such as insulin to where they’re needed, the business will continue to invest and innovate to bring new products to the market.

With its Releye® range, which includes the biggest thermally-controlled container available, Envirotainer can ensure minimal or zero temperature deviations on the shipments and virtually zero product loss. Releye® also offers integrated live monitoring, which enables a unique insight into product condition, location and progress of the shipment. The company also supports cryogenic -70°C dry ice shipping for products such as clinical trials, vaccines, diagnostics biospecimen and many more with its CryoSure® product line.

Fredrik Linnér, Chief Business Development Officer at Envirotainer said, “The increase in our shipments reflects the huge need for efficient, secure and sustainable cold-chain solution for transporting sensitive pharmaceuticals We will continue to increase capacity, developing our product range and accelerating the digitalisation of the cold-chain industry. The need to safely transport pharmaceuticals while minimising wasted space in precious air cargo is unlikely to go away and we will be ready to help our customers move life-saving medicines where they need to be.”